BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, January 7, 2025
Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards
See today's BioWorld Science
Home
» Bright Peak Therapeutics reports on Treg enhancer autoimmune disease programs
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immune
Bright Peak Therapeutics reports on Treg enhancer autoimmune disease programs
Nov. 7, 2022
No Comments
Interleukin-2 (IL-2) plays essential roles in immune system function, controlling tolerance and immunity. From the thymus, IL-2 prevents autoimmune disease by promoting the differentiation of immature T cells to regulatory T cells (Tregs).
BioWorld Science
Conferences
Immune